Patents by Inventor Elena Barbanti
Elena Barbanti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8846763Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides, and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to a reduction reaction with a reducing agent selected from sodium borohydride and potassium borohydride in an appropriate amount of an organic solvent selected from C1-C5 lower alkanols, allowing the formation and presence during a substantial position of the reduction reaction course of a suspension of the Schiff base into the saturated solution of the Schiff base into the same organic solvent.Type: GrantFiled: August 7, 2013Date of Patent: September 30, 2014Assignee: Newron Pharmaceuticals, S.p.A.Inventors: Elena Barbanti, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Patent number: 8697738Abstract: Methods of using certain ?-aminoamide derivatives in the treatment of RLS and addictive disorders, The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.Type: GrantFiled: March 15, 2013Date of Patent: April 15, 2014Assignee: Newron Pharmaceuticals S.p.A.Inventors: Claudia Besana, Elena Barbanti, Emanuela Izzo, Florian Thaler, Ruggero Fariello, Patricia Salvati, Luca Benatti
-
Publication number: 20140051758Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides, and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to a reduction reaction with a reducing agent selected from sodium borohydride and potassium borohydride in an appropriate amount of an organic solvent selected from C1-C5 lower alkanols, allowing the formation and presence during a substantial position of the reduction reaction course of a suspension of the Schiff base into the saturated solution of the Schiff base into the same organic solvent.Type: ApplicationFiled: August 7, 2013Publication date: February 20, 2014Applicant: Newron Pharmaceuticals S.p.A.Inventors: Elena BARBANTI, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Patent number: 8530701Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base.Type: GrantFiled: December 1, 2008Date of Patent: September 10, 2013Assignee: Newron Pharmaceuticals, S.p.A.Inventors: Elena Barbanti, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Patent number: 8445539Abstract: The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.Type: GrantFiled: June 15, 2010Date of Patent: May 21, 2013Assignee: Newron Pharmaceuticals S.p.A.Inventors: Emanuela Izzo, Laura Faravelli, Elena Barbanti, Patricia Salvati
-
Patent number: 8445513Abstract: The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.Type: GrantFiled: April 19, 2005Date of Patent: May 21, 2013Assignee: Newron Pharmaceuticals S.p.A.Inventors: Claudia Besana, Elena Barbanti, Emanuela Izzo, Florian Thaler, Ruggero Fariello, Patricia Salvati, Luca Benatti
-
Patent number: 8278485Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.Type: GrantFiled: November 3, 2011Date of Patent: October 2, 2012Assignee: Newron Pharmaceuticals S.p.A.Inventors: Elena Barbanti, Carla Caccia, Patricia Salvati, Francesco Velardi, Tiziano Ruffilli, Luigi Bogogna
-
Publication number: 20120157712Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.Type: ApplicationFiled: November 3, 2011Publication date: June 21, 2012Applicant: NEWRON PHARMACEUTICALS S.P.A.Inventors: ELENA BARBANTI, CARLA CACCIA, PATRICIA SALVATI, FRANCESCO VELARDI, TIZIANO RUFFILLI, LUIGI BOGOGNA
-
Patent number: 8076515Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.Type: GrantFiled: December 18, 2008Date of Patent: December 13, 2011Assignee: Newron Pharmaceuticals S.p.A.Inventors: Elena Barbanti, Carla Caccia, Patricia Salvati, Francesco Velardi, Tiziano Ruffilli, Luigi Bogogna
-
Publication number: 20110184068Abstract: The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role.Type: ApplicationFiled: November 4, 2010Publication date: July 28, 2011Applicant: Newron Pharmaceuticals S.p.A.Inventors: Elena Barbanti, Florian Thaler, Carla Caccia, Ruggero Fariello, Patricia Salvati
-
Publication number: 20110014304Abstract: The disclosure relates to pharmacotherapy of a psychiatric disorder which is schizophrenia and/or anxiety, wherein schizophrenia includes schizophrenia related disorders such as brief psychotic disorders, delusional disorders, schizoaffective disorders, and schizophreniform disorders, and anxiety includes panic disorders, obsessive-compulsive disorders (OCD), post-traumatic stress disorders (PTSD), social phobia or social anxiety disorders, specific phobia, and generalized anxiety disorders (GAD). The compounds of the disclosure are useful for the treatment of the above psychiatric disorders alone or in combination with other therapeutical agents effective in the treatment of schizophrenia and/or anxiety disorders.Type: ApplicationFiled: June 15, 2010Publication date: January 20, 2011Applicant: Newron Pharmaceuticals S.p.A.Inventors: Emanuela Izzo, Laura Faravelli, Elena Barbanti, Patricia Salvati
-
Publication number: 20100324141Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]-propanamides and their salts with pharmaceutically acceptable acids with a high degree of purity, i.e. with a content of dibenzyl derivatives impurities lower than 0.03% by weight. The process is carried out by submitting a Schiff base intermediate to a reduction reaction with a reducing agent in an amount of organic solvent to allow the formation (and presence during a substantial portion of the reduction reaction) of a suspension of the Schiff base.Type: ApplicationFiled: December 1, 2008Publication date: December 23, 2010Applicant: NEWRON PHARMACEUTICALS S.P.A.Inventors: Elena Barbanti, Laura Faravelli, Patricia Salvati, Renato Canevotti, Francesco Ponzini
-
Patent number: 7718815Abstract: Methods of using certain ?-aminoamide derivatives to treat lower urinary tract disorders. The therapeutic agents of the invention are able to reduce or even stop the lower urinary tract disorders substantially without side effects.Type: GrantFiled: January 20, 2005Date of Patent: May 18, 2010Assignee: Newron Pharmaceuticals S.p.A.Inventors: Elena Barbanti, Orietta Veneroni, Florian Thaler, Roberto Pellicciari, Luca Benatti, Patricia Salvati
-
Publication number: 20100016440Abstract: Methods of using certain a-aminoamide derivatives as anti-inflammatory agents. The anti-inflammatory agents of the invention are able to reduce or even stop inflammatory s conditions substantially without side effects.Type: ApplicationFiled: August 20, 2009Publication date: January 21, 2010Applicant: NEWRON PHARMACEUTICALS S.P.A.Inventors: Patricia Salvati, Orietta Veneroni, Elena Barbanti, Fariello Ruggero, Luca Benatti
-
Publication number: 20090156678Abstract: A process for obtaining therapeutically active 2-[4-(3- and 2-(fluorobenzyloxy)benzylamino]propanamides and their salts with pharmaceutically acceptable acids with high purity degree, in particular, with a content of dibenzyl derivatives impurities lower than 0.03%, preferably lower than 0.01% by weight. The process is carried out by submitting the Schiff bases intermediates 2-[4-(3- and 2-fluorobenzyloxy)benzylideneamino]propanamides to catalytic hydrogenation in the presence of a heterogeneous catalyst in a protic organic solvent.Type: ApplicationFiled: December 18, 2008Publication date: June 18, 2009Applicant: NEWRON PHARMACEUTICALS S.P.A.Inventors: Elena Barbanti, Carla Caccia, Patricia Salvati, Francesco Velardi, Tiziano Ruffilli, Luigi Bogogna
-
Publication number: 20080132567Abstract: Methods of using certain ?-aminoamide derivatives to treat lower urinary tract disorders. The therapeutic agents of the invention are able to reduce or even stop the lower urinary tract disorders substantially without side effects.Type: ApplicationFiled: January 20, 2005Publication date: June 5, 2008Inventors: Elena Barbanti, Orietta Veneroni, Florian Thaler, Roberto Pellicciari, Luca Benatti, Patricia Salvati
-
Publication number: 20080096965Abstract: The invention relates to the use of selected (R)-2-[(halobenzyloxy)benzylamino]-propanamides and the pharmaceutically acceptable salts thereof for the manufacture of medicament, that are selectively active assodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, pain, migraine, periferal diseases, cardiovascular diseases, inflammatory processes affecting all body systems, disorders affecting skin and related tissues, disorders of the respiratory system, disorders of the immune and endocrinological systems, gastrointestinal, urogenital, metabolic and seizure disorders, where the above mechanisms have been described as playing a pathological role.Type: ApplicationFiled: July 28, 2005Publication date: April 24, 2008Applicant: NEWRON PHARMACEUTICALS S.p.A.Inventors: Elena Barbanti, Florian Thaler, Carla Caccia, Ruggero Fariello, Partricia Salvati
-
Publication number: 20070276046Abstract: Methods of using certain a-aminoamide derivatives as anti-inflammatory agents. The anti-inflammatory agents of the invention are able to reduce or even stop inflammatory s conditions substantially without side effects.Type: ApplicationFiled: April 22, 2004Publication date: November 29, 2007Inventors: Patricia Salvati, Orietta Veneroni, Elena Barbanti, Fariello Ruggero, Luca Benatti
-
Publication number: 20070203182Abstract: The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.Type: ApplicationFiled: April 19, 2005Publication date: August 30, 2007Inventors: Claudia Besana, Elena Barbanti, Emanuela Izzo, Florian Thaler, Ruggero Fariello, Patricia Salvati, Luca Benatti
-
Patent number: 5436154Abstract: A monoclonal antibody is provided which is able to neutralize both human TNF .alpha. and TNF .beta., or a binding fragment thereof. A stable hybridoma cell line and progeny thereof are also provided which secrete such a monoclonal antibody. The monoclonal antibody or a fragment thereof may be used to detect the content of human TNF in a sample of body fluid.Type: GrantFiled: December 13, 1991Date of Patent: July 25, 1995Assignee: Farmitalia Carlo Erba S.R.L.Inventors: Elena Barbanti, Marta Ghislieri, Fabrizio Marcucci, Domenico Trizio